A prospective study of management of chemotherapy induced adverse event for breast cancer.

A prospective study of management of chemotherapy induced adverse event for breast cancer. - Management of chemotherapy induced adverse event

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009855

Enrollment

Registered

2013-01-24

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Management of these chemotherapy induced adverse event. 1. Neurotoxicity Taxane 2. Nausea and Vomitting Anthracyclin 3. Skin disorder Taxane Lapatinib

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1) Histologically confirmed invasive breast cancer by biopsy and treatment of Taxanes/Anthracyclin/Lapatinib. 2) >=20years old 3) Written informed consent

Exclusion criteria

Exclusion criteria: Exclusion Criteria 1) Hypersensitivity of protocol therapy 2) Uncontrolled infection, diarrhea, bowel obstruction, diabetes, myocardinal infarction, heart failure, pulmonary fibrosis, pneumonitis, cerebrovascular disorder, other. 3) Active brain metastasis 4) Mental disorder 5) Severe myelosupression, renal and hepatic disfunction. 6) ascetic and pleural fluid 7) Pregnant, lactating or declined contraception 8) Patients considered ineligible by the attending physician

Design outcomes

Primary

Measure	Time frame
Proportion of >= Grade 3 adverse event	—

Secondary

Measure	Time frame
QOL Proportion of all Grade adverse event	—

Countries

Japan

Contacts

Public ContactHiromi Okuyama

Showa University Department of Breast Surgical Oncology

breastc@med.showa-u.ac.jp03-3784-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026